Floatz logo

Atropine

Cognitive Disorder

New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
73/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Quetiapine
Emory University
Phase 4BB
Levodopa
Vanderbilt University Medical Center
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

Atropine is also rated in:

cardiac rhythm diseaseDormant
BB
Indicative · Phase 4
68 / 100
View asset →
respiratory paralysisDormant
BB
Indicative · Phase 4
68 / 100
View asset →
breast adenocarcinomaDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →